MRK Stock Recent News
MRK LATEST HEADLINES
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD drug manufacturer Verona Pharma for $10 billion, adding yet another potential blockbuster to its expanding collection of post-Keytruda assets.
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from the discount bin.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals n.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts New Drug Application for Merck's DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.
Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both bearish and bullish action ahead.
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, INMune Bio, Nutex Health, LyondellBasell, Shopify, IBIT:CA and BITO are rated Strong Buy or Buy. MSTY is rated Hold.